Viral dynamics of HIV: Implications for drug development and therapeutic strategies

Annals of Internal Medicine

Volumn 124, Issue 11, 1996, Pages 984-994

  Havlir, Diane V ^a   Richman, Douglas D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DEVELOPMENT; DRUG RESISTANCE; DYNAMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; VIREMIA; VIRUS REPLICATION;

EID: 0030317890     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-11-199606010-00006     Document Type: Article

References (112)

1. Albert J, Gaines H, Sonnerborg A, Nystrom G, Pehrson PO, Chiodi F, et al. Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. J Med Virol. 1987;23:67-73.
2. Falk LA Jr, Paul D, Landay A, Kessler H. HIV isolation from plasma of HIV-infected persons [Letter], N Engl J Med. 1987;316:1547-8.
3. Ehrnst A, Sonnerborg A, Bergdahl S, Strannegard O. Efficient isolation of HIV from plasma during different stages of HIV infection. J Med Virol. 1988;26:23-32.
4. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989;321: 1621-5.
5. Coombs RW, Collier AC Allain JP, Nikora B, Leuther MD, Gjerset GF, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989;321:1626-31.
6. + lymphocyte levels. J Infect Dis. 1991;164:72-80.
7. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiencyvirus type 1 infection. N Engl J Med. 1991;324:961-4.
8. Phillips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science. 1996;271:497-9.
9. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991;324:954-60.
10. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-5.
11. Jackson JB, Kwok SY, Sninsky JJ, Hopsicker JS, Sannerud KJ, Rhame FS, et al. Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals. J Clin Microbiol. 1990;28:16-9.
12. Sönnerborg AB, Ehrnst AC, Bergdahl SK, Pehrson PO, Sköldenberg BR, Strannegård ÖO. HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS. 1988;2:89-93.
13. Hollander H, Levy JA. Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid Ann Intern Med. 1987;106: 692-5.
14. Armstrong JA, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet. 1984;2:370-2.
15. Epstein LG, Sharer LR, Cho ES, Myenhofer M, Navla BA, Price RW. HTLV-III/LAV-like retrovirus particles in the brains of patients with AIDS encephalopathy. AIDS Res. 1984-85;1:447-54.
16. Baroni CD, Pezzella F, Mirolo M, Ruco LP, Rossi GB. Immunohistochemical demonstration of p24 HTLV III major core protein in different cell types within lymph nodes from patients with lymphadenopathy syndrome (LAS). Histopathology. 1986;10:5-13.
17. Biberfeld P, Chayt KJ, Marselle LM, Biberfeld G, Gallo RC, Harper ME. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol. 1986;125:436-42.
18. Warner TF, Gabel C, Hafez GR, Uno H, Borcherding WR. Type D retrovirus in prodromal AIDS? [Letter], Lancet. 1984;1:860
19. Tenner-Racz K, Racz P, Dietrich M, Kern P. Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy [Letter]. Lancet. 1985;1:105-6.
20. Tenner-Racz K, Racz P, Bofill M, Schulz-Meyer A, Dietrich M, Kern P, et al. HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. Am J Pathol. 1986;123: 9-15.
21. Le Tourneau A, Audouin J, Diebold J, Marche C, Tricottet V, Reynes M. LAV-like viral particles in lymph node germinal centers in patients with the persistent lymphadenopathy syndrome and the acquired immunodeficiency syndrome-related complex: an ultrastructural study of 30 cases. Hum Pathol. 1986;17:1047-53.
22. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986;83:7089-93.
23. Pantaleo G, Graziosl C, Demarest JF, Butini L, Montronl M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-8.
24. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-62.
25. Patterson BK, Till M, Otto P, Goolsby C Furtado MR, McBride LJ, et al. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cylometry. Science. 1993;260:976-9.
26. Bagasra O, Hauptman SP, Lischner HW, Sachs M, Pomerantz RJ. Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med. 1992;326:1385-91.
27. Sei S, Kleiner DE, Kopp JB, Chandra R, Klotman PE, Yarchoan R, et al. Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction. J Infect Dis. 1994;170:325-33.
28. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
29. van Gemen B, van Beuningen R, Nabbe A, van Strijp D, Jurriaans S, Lens P, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Viral Methods. 1994;49:157-67.
30. Urdea MS, Wilber JC, Yeghiazarian T, Todd JA, Kern DG, Fong SI, et al. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS. 1994;7(Suppl 2):S11-4.
31. Dewar RL, Highbarger HC Sarmiento MD, Todd JA, Vasudevachari MB, Davey RT Jr, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma J Infect Dis. 1994;170:1172-9.
32. Fiscus SA, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA 3d, LoFaro ML, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis. 1996;171:305-11.
33. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259:1749-54.
34. Jurriaans S, van Gemen B, Weverling GJ, van Strijp D, Nara P, Coutinho R, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology. 1994;204:223-33.
35. Winters MA, Tan LB, Katzenstein DA, Merigan TC. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol. 1993;31:2960-6.
36. Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, Shaw GM, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:305-10.
37. + cell count and clinical diagnosis of AIDS [Abstract]. HIV Drug Resistance Third International Workshop. Kauai, Hawaii: 2-5 August 1994.
38. Mellon JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoc BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-9.
39. Henrard DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, et al. Natural history of HIV-1 cell-free viremia. JAMA. 1995;274:554-8.
40. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
41. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarcst JF, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995;332:209-16.
42. Ho DD. HIV-1 viraemia and influenza [Letter]. Lancet. 1992;339:1549.
43. Hamilton B, Follansbee S, Staprans S, Elbeik T, Feinberg M. Increased HIV plasma viremia after influenza vaccine. 2nd National Conference on Human Retroviruses and Related Infections [Abstract]. Washington, DC: 29 January-2 February 1995.
44. Mole L, Ripich S. Margolis D, Holodniy M. Plasma HIV RNA levels are increased during active herpes simplex virus infection. 2nd National Conference on Human Retroviruses and Related Infections [Abstract). Washington, DC: 29 January-2 February 1995.
45. Brkhacek B, Swindells S, Janoff E, Stevenson M. Immune activation and control of viral burden in AIDS. 2nd National Conference on Human Retroviruses and Related Infections [Abstract]. Washington, DC: 29 January-2 February 1995.
46. Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci U S A. 1995;92:6017-21.
47. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-6.
48. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-22.
49. Havlir D, Eastman S, Richman DD. HIV-1 kinetics: rates of production and clearance of viral populations in asymptomatic patients treated with nevirapine [Abstract]. First National Conference on Human Retroviruses and Related Infections, Washington, DC; January 1995.
50. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifetime, and viral generation time. Science. 1996;271:1582-6.
51. Loveday C Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IV, et al. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet. 1995;345:820-4.
52. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-9.
53. Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Safety and activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). 3rd National Conference on Human Retroviruses and Related Infections [Abstract]. Washington, DC: 29 January-1 February 1996.
54. Holland JJ, De La Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microbiol Immunol. 1992;176:1-20.
55. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087-94.
56. Koup RA. Virus escape from CTL recognition [Comment]. J Exp Med. 1994; 180:779-82.
57. Richman DD. Drug resistance in relation to pathogenesis. AIDS. 1995; (Suppl A):S49-53.
58. Zhang LQ, Simmonds P, Ludlam CA, Brown AJ. Detection, quantification and sequencing of HIV-1 from plasma of seropositive individuals and from factor VIII concentrates. AIDS. 1991;5:675-81.
59. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high density oligonucleotide arrays: implications for therapy. Nature Medicine. [In press].
60. Jacobsen H, Haenggi M, Ott M, Duncan IB, Andreoni M, Vella S, et al. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials [Abstract]. 4th International HIV Drug Resistance Workshop, Sardinia Italy; 6-9 July 1995.
61. Nájera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses. 1994;10:1479-88,
62. Nájera I, Holguín A, Quiñones-Mateu ME, Muñoz-Fernández MA, Nájera R, López-Galíndez C, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol, 1995;69:23-31.
63. Schinazi RF, Lloyd RM Jr. Nguyen MH, Cannon DL, McMillan A, Ilksoy N, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37: 875-81.
64. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-6.
65. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1993;37:1390-2.
66. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991;65:4887-92.
67. Richman DO, Shih CK, Lowy I. Rose J, Prodanovich P, Goff S, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA. 1991;88:11241-5.
68. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-9.
69. Saag MS, Emini EA, Laskin OU Douglas I, Lapidus WI, Schleif WA, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993;329:1065-72.
70. Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL Hall D, et al. Phase I/I1 evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:141-51.
71. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-6.
72. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171:537-45.
73. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-4.
74. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246:1155-8.
75. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC. et al. In vim emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-71.
76. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A. [In press].
77. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-9.
78. 2-symmetric protease inhibitor. J Virol. 1994;68: 2016-20
79. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, et al. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis. 1994;169:713-21.
80. Jurriaans S, Weverling GJ, Goudsmit J, Boogaard J, Brok M, van Strijp D, et al. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. AIDS Res Hum Retroviruses. 1995; 11:473-9.
81. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis. 1995;172:1379-83.
82. Fischl MA, Richman DD, Flexner C, Meehan P, Para MF, Haubrich R, et al. Phase I study of two formulations and dose schedules of SC-52151, a protease inhibitor [Abstract]. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC: 29 January-2 February 1995.
83. 3 [Abstract], 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: 17-20 September 1995.
84. Katzenstein D, Hammer S, Hughes M, Gundacker H, Jackson B, Merigan T, et al. Plasma virion RNA in response to early antiretroviral drug therapy in ACTG 175. Do changes in virus load parallel clinical and immunologic outcomes [Abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: 17-20 September 1995.
85. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelll C Liou S-H, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992;327:581-7.
86. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-31.
87. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, De Gruttola V, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995;122:401-8.
88. Richman DD, Bozzette SA. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994; 169:968-74.
89. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995;332:228-32.
90. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995;270: 988-91.
91. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995;333:1662-9.
92. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 1993; 91:2326-33.
93. Meng TC, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study Ann Intern Med. 1992;115:13-20.
94. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993;119:786-93.
95. Yarchoan R, Lietzau JA, Nguyen BY, Brawley OW, Pluda JM, Saville MW, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis. 1994;169:9-17.
96. 3 [Abstract]. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC: 29 January-2 February 1995.
97. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528-33.
98. Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. Ann Intern Med. 1994;120:360-8.
99. Chow YK, Hirsch MS, Merrill DP, Bechtel U, Eron JJ, Kaplan JC, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature. 1993;361:650-4.
100. Erickson JW. The not-so-great escape [News]. Nature Struct Biol. 1995;2: 523-9.
101. Kinloch-De Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995;333:408-13.
102. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990; 322:941-9.
103. Cooper DA, Gated JM, Kroon S, Clumeck N, Millard J, Goebel FD, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 1993;329:297-303.
104. Rouzioux C. Prevention of maternal HIV transmission. Practical guidelines. Drugs. 1995;49(Suppl 1): 17-24.
105. Weiser B, Nachman S, Trapper P, Viscosi KH, Crimson R, Baxter G, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci U S A. 1994;91:8037-41.
106. Dickover K, Herman S, Garratty E, von Seidlein L, Boyer P, Bryson Y. Maternal HIV RNA levels are directly related to perinatal transmission risk and significantly reduced by ZDV treatment (Abstract). J Cell Biochem. 1995; S21B:233.
107. Koup RA, Cao Y, Ho DD, Krogstad PA, Chen ISY, Korber BTM, et al. Lack of maternal viral threshold for vertical transmission of HIV-1 [Abstract], 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC: 28 January-1 February 1996.
108. Burchett SK, Komegay J, Pitt J, Landesman S, Rosenblatt H, Hillyer G, et al. Assessment of maternal plasma HIV viral load as a correlate of vertical transmission [Abstract], 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC: 28 January-1 February 1996.
109. Dickover RE, Dillon M, Gillette SG, Deveikis A, Keller M, Plaeger-Marshall S, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis. 1994;170:1279-84.
110. Connor EM, Sperling RS, Gelber R, Klselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-80.
111. Masquelier B, Lemoigne E, Pellegrin I, Douard D, Sandier B, Fleury HJ. Primary infection with zidovudine-resistant HIV [Letter]. N Engl J Med. 1993;329:1123-4.
112. Frenkel LM, Wagner LE 2d, Demeter LM, Dewhurst S, Coombs RW. Murante BL, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20:1321-6.